Zhang Guowei | Pharmaceutical Sciences | Excellence in Research

Posted on by The Scientist

Mr. Zhang Guowei | Pharmaceutical Sciences | Excellence in Research

Associate Professor |  Hebei University | China

Dr. Zhang Guowei is an active researcher whose work advances the understanding of psychological health, behavioral patterns, and population-level mental well-being, particularly among young adults in contemporary social environments. His academic influence is demonstrated through 347 citations, 20 publications, and an h-index of 10, reflecting a growing global presence and measurable scholarly impact. His research portfolio integrates empirical analysis, psychometric assessment, and digital-behavior analytics to examine how social, environmental, and technological factors shape mental health outcomes. Dr. Zhang’s contributions include impactful studies on anxiety, depression, insomnia, and PTSD among university students, offering timely insights into evolving psychosocial challenges in the post-pandemic era. His work on time-based online survey patterns and their relationship with offline psychological symptoms provides a novel methodological approach, highlighting his ability to connect digital behavioral traces with real-world psychological states. Through these interdisciplinary inquiries, he addresses urgent public-health concerns and informs evidence-based interventions. With a collaborative network spanning over 70 co-authors, Dr. Zhang actively participates in multi-institutional and cross-regional research efforts. This broad collaborative engagement enhances the robustness of his findings and contributes to the global dialogue on mental health resilience, student well-being, and psychosocial risk assessment. His publications in reputable international journals underscore his commitment to research transparency, open access, and data-driven decision-making. Dr. Zhang’s ongoing work strengthens the academic and societal understanding of mental-health dynamics in rapidly changing environments, emphasizing early detection, preventive strategies, and policy relevance. His scholarly trajectory continues to advance applied psychological research, contributing meaningful evidence to public health systems, educational institutions, and community well-being initiatives worldwide.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

  1. Xiong, J.-M., Wang, J.-Y., Liu, Y., … Zhang, G.-W. (2023). Study on prescription medication mode and mechanism of traditional Chinese medicine in the treatment of noncritical COVID-19 based on data mining.

  2. Fu, Z.-T., Wang, J.-Y., Liu, Y., … Zhang, G.-W. (2023). The mechanism of TCM prevention and treatment of heavy COVID-19 based on data mining and network pharmacology.

  3. Zhang, L.-H., Zhang, W.-Y., Xiong, J.-M., … Zhang, G.-W. (2022). Mechanisms of Compound Kushen Injection for the treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation.

  4. Cui, Q., Ma, Y., Yu, H., … Zhang, G.-W. (2021). Systematic analysis of the mechanism of hydroxysafflor yellow A for treating ischemic stroke based on network pharmacology technology.

  5. Zhang, L., Zhang, W., Xiong, J., … Zhang, G.-W. (2020). Mechanisms of Compound Kushen Injection for treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation.

Yanan Yang | Pharmaceutical Sciences | Research Excellence Award

Posted on by The Scientist

Ms. Yanan Yang | Pharmaceutical Sciences | Research Excellence Award

Student | Tianjin University of Traditional Chinese Medicine | China

Dr. Yanan Yang is a researcher at Tianjin University of Traditional Chinese Medicine, recognized for her contributions at the intersection of gut microbiota, metabolic regulation, and cardiometabolic diseases. Her scholarly influence is demonstrated by 726 citations, 45 peer-reviewed publications, and an h-index of 14, underscoring her growing impact in biomedical and translational health research. Dr. Yang’s work spans gut microbiome dynamics, microbial metabolites, metabolic disorders, traditional Chinese medicine mechanisms, and multi-omics integration. She has contributed to high-visibility studies on acute coronary syndrome, cardiovascular disease mechanisms, type 2 diabetes regulation, and herbal-medicine-induced metabolic modulation. Her involvement in multi-center collaborations—including meta-analyses with large participant cohorts—reflects her ability to bridge clinical findings with microbiome-mediated insights. Dr. Yang’s publications highlight a consistent focus on understanding microbial signatures, therapeutic pathways, and host–microbe interactions to advance preventive and precision medicine. She has also engaged in studies evaluating herbal interventions such as Coptis chinensis, showcasing the integration of traditional medicine with modern biomedical evidence. With over 223 co-authors across her publication record, her collaborative networks extend nationally and internationally, supporting multidisciplinary innovation in gut–heart metabolic axis research. Dr. Yang’s ongoing contributions provide essential foundations for developing microbiome-based diagnostics, therapeutic strategies for metabolic diseases, and evidence-based applications of traditional Chinese medicine, reflecting her role as an emerging and influential scientist in her field.

Featured Publications

  1. Wu, C., Zhao, Y., Zhang, Y., Yang, Y., Su, W., Yang, Y., Sun, L., Zhang, F., Yu, J., … (2022). Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates prediction of BBR’s cholesterol-lowering efficacy in patients. Journal of Advanced Research, 37, 197–208. Cited by: 78

  2. Dong, C., Yang, Y., Wang, Y., Hu, X., Wang, Q., Gao, F., Sun, S., Liu, Q., Li, L., Liu, J., … (2023). Gut microbiota combined with metabolites reveals unique features of acute myocardial infarction compared with stable coronary artery disease. Journal of Advanced Research, 46, 101–112. Cited by: 74

  3. Dong, C., Yu, J., Yang, Y., Zhang, F., Su, W., Fan, Q., Wu, C., & Wu, S. (2021). Berberine, a potential prebiotic to indirectly promote Akkermansia growth through stimulating gut mucin secretion. Biomedicine & Pharmacotherapy, 139, 111595. Cited by: 74

  4. Yang, Y. N., Wang, Q. C., Xu, W., Yu, J., Zhang, H., & Wu, C. (2022). The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet-induced hyperlipidemia and stimulates liver LDLR expression. Biomedicine & Pharmacotherapy, 155, 113749. Cited by: 60

  5. Xu, W., Yu, J., Yang, Y., Li, Z., Zhang, Y., Zhang, F., Wang, Q., Xie, Y., Zhao, B., & Wu, C. (2023). Strain-level screening of human gut microbes identifies Blautia producta as a new anti-hyperlipidemic probiotic. Gut Microbes, 15(1), 2228045. Cited by: 57